Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06526793 · ClinicalTrials.gov registry record · Phase 2

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

A Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL), sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
20
Study locations

NCT06526793 is a Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 240 participants, above the 120-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06526793, a Phase 2 study of B-Cell Non-Hodgkin Lymphoma and Follicular Lymphoma (FL), is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modules: Module 1 for FL and Module 2 for LBCL.

Conditions Studied

B-Cell Non-Hodgkin Lymphoma Follicular Lymphoma (FL) Large B-Cell Lymphoma (LBCL)

Interventions

  • DRUG Surovatamig

Study Locations (20)

Pennsylvania

  • Research Site - Philadelphia
  • Research Site - Pittsburgh
  • Research Site - Pittsburgh

Florida

  • Research Site - Jacksonville
  • Research Site - Tampa

Iowa

  • Research Site - Iowa City
  • Research Site - Waukee

Arizona

  • Research Site - Phoenix

California

  • Research Site - Duarte

Illinois

  • Research Site - Chicago

Kansas

  • Research Site - Overland Park

Minnesota

  • Research Site - Rochester

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2024-11-27
Est. Completion 2029-06-14
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06526793

The ClinicalTrials.gov registry entry for NCT06526793 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 120-participant average among 24 other B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (100% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Surovatamig is the first listed.

NCT06526793 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Pennsylvania, Florida, Iowa.

Frequently Asked Questions

What is clinical trial NCT06526793 about?

NCT06526793 is a clinical study titled "Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL". This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior lines of therapies. The study has 2 Modu...

What is the current status of trial NCT06526793?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2024-11-27. Estimated completion is 2029-06-14.

What conditions does trial NCT06526793 study?

This clinical trial studies the following conditions: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL).

What interventions are being tested in trial NCT06526793?

The interventions under investigation include: Surovatamig (DRUG).

Who is sponsoring clinical trial NCT06526793?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06526793 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-Cell Non-Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-Cell Non-Hodgkin Lymphoma

All registered trials for this condition

Follicular Lymphoma (FL)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.